{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-203000","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.561173+00:00","generated_at":"2026-06-12T09:17:14.743135+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Terns CEO Senthil Sundaram resigns for health reasons; Erin Quirk assumes leadership as principal executive officer","bullets":["Senthil Sundaram resigned as CEO and Board member due to health reasons previously disclosed in January 2022.","Erin Quirk, M.D., President and Head of R&D, assumed leadership effective immediately as principal executive officer.","Sundaram will remain as a Senior Advisor to the company.","Company plans three key clinical data readouts across three programs by end of 2024; balance sheet supports milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-203000","json":"https://secwatch.observer/filing/0001193125-23-203000.json","markdown":"https://secwatch.observer/filing/0001193125-23-203000.md","text":"https://secwatch.observer/filing/0001193125-23-203000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000119312523203000/0001193125-23-203000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000119312523203000/d509174d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:17:14.743135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}